New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data (Q30578338)

25 June 2017

1 reference

title

New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data (English)

1 reference

25 June 2017

Dushyantha Jayaweera

1

1 reference

25 June 2017

Paula Dilanchian

series ordinal

2

1 reference

25 June 2017

language of work or name

English

0 references

publication date

1 December 2012

1 reference

Expert Opinion on Pharmacotherapy

25 June 2017

published in

1 reference

25 June 2017

volume

13

1 reference

25 June 2017

issue

18

1 reference

25 June 2017

page(s)

2601-2612

1 reference

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

25 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Rilpivirine: a new addition to the anti-HIV-1 armamentarium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Class-sparing regimens for initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 V

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.742506

10.1517/14656566.2012.742506

21 January 2018

Identifiers

DOI

1 reference

25 June 2017

1 reference